TUBB1 tubulin beta 1 class VI
ENSG00000101162 · protein coding · Open Targets profile
Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, High-Quality Ligand, Druggable Family
- PROTAC
- Database Ubiquitination, Half-life Data, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 1.2378000020980835 (upper bound 1.697100043296814). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against TUBB1 (glembatumumab vedotin, vinflunine, polatuzumab vedotin, vinorelbine, vincristine, mirvetuximab soravtansine, vinblastine, paclitaxel poliglumex, ixabepilone, eribulin, brentuximab vedotin, tisotumab vedotin), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Alex F HerreraCity of Hope Medical Center · 5 of 5 trials Phase 2+
- Elias JabbourM.D. Anderson Cancer Center · 4 of 4 trials Phase 2+Ph2NCT01424982 · Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemiabrief
- Elizabeth A MullenChildren's Oncology Group · 3 of 3 trials Phase 2+
- Min YanHenan Cancer Hospital · 3 of 3 trials Phase 2+
- Seth E. KarolSt. Jude Children's Research Hospital · 3 of 3 trials Phase 2+Ph1/Ph2NCT05192889 · Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclaxbrief
- Bristol-Myers SquibbBristol-Myers Squibb · 2 of 3 trials Phase 2+Ph2NCT06425302 · A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphomabrief
- Joseph M TuscanoCity of Hope Comprehensive Cancer Center LAO · 2 of 3 trials Phase 2+Ph1NCT06015880 · Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphomabrief
- Alex HerreraCity of Hope Medical Center · 2 of 2 trials Phase 2+
- Alison MoskowitzMemorial Sloan Kettering Cancer Center · 2 of 2 trials Phase 2+
- Amar GajjarSt. Jude Children's Research Hospital · 2 of 2 trials Phase 2+
- Binghe XuOncology Hospital, Chinese Academy of Medical Sciences · 2 of 2 trials Phase 2+
- Carlos Rodriguez-GalindoNorth American Consortium for Histiocytosis · 2 of 2 trials Phase 2+
- Dai ChiharaUT MD Anderson Cancer Center · 2 of 2 trials Phase 2+
- David McCallM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
- Elena ParovichnikovaNational Research Center for Hematology · 2 of 2 trials Phase 2+
Registry trials of glembatumumab vedotin, vinflunine, polatuzumab vedotin, vinorelbine, vincristine, mirvetuximab soravtansine, vinblastine, paclitaxel poliglumex, ixabepilone, eribulin, brentuximab vedotin, tisotumab vedotin updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 250 of 382 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 18 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
363 trials of drugs against TUBB1 were stopped early; 17 of the 200 most recent give no reason
Terminated, withdrawn and suspended interventional trials of glembatumumab vedotin, vinflunine, polatuzumab vedotin, vinorelbine, vincristine, mirvetuximab soravtansine, vinblastine, paclitaxel poliglumex, ixabepilone, eribulin, brentuximab vedotin, tisotumab vedotin, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 363.
- terminated · 2026-10-16 · Henan Cancer Hospital · Eribulin and Tucidinostat“The anticipated efficacy was not achieved; the primary objective of Stage 1 in the Simon-2 design was not met.”
- terminated · 2026-10-15 · Spanish Breast Cancer Research Group · Vinorelbine, Eribulin“Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study completion.”
- terminated · 2026-10-05 · Children's Oncology Group · Vincristine Sulfate“Drug supply issues”
- suspended · 2026-09-29 · University of Washington · Vincristine“Safety Review”
- withdrawn · 2026-09-24 · Case Comprehensive Cancer Center · matched by the registry's drug synonyms“PI left institution”
- terminated · 2026-09-21 · Institut Claudius Regaud · Zolinza (vorinostat), vinorelbineNo reason given
- terminated · 2026-09-18 · Pusan National University Yangsan Hospital · matched by the registry's drug synonyms“Poor accrual due to increased use of alternative neoadjuvant treatment options.”
- terminated · 2026-09-17 · Centre Oscar Lambret · Vinblastine“Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).”
- suspended · 2026-09-01 · CStone Pharmaceuticals · Vincristine“The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.”
- terminated · 2026-07-30 · M.D. Anderson Cancer Center · Vincristine Sulfate“the study was closed early due to competing trials”
- terminated · 2026-07-22 · Seagen, a wholly owned subsidiary of Pfizer · Tisotumab Vedotin“Sponsor has decided to stop the trial based on strategic decisions”
- suspended · 2026-06-15 · University of Alabama at Birmingham · Brentuximab vedotin“IRB audit”
- withdrawn · 2026-05-14 · Institute of Hematology & Blood Diseases Hospital, China · matched by the registry's drug synonyms“drug-associated adverse reactions”
- terminated · 2026-05-13 · M.D. Anderson Cancer Center · Vincristine“<75% participation”
- terminated · 2026-04-16 · UNC Lineberger Comprehensive Cancer Center · Polatuzumab vedotin (PV)“Funding”
- withdrawn · 2026-04-01 · Eric Jacobsen, MD · Vincristine“Ipsen requested a temporary closure due to a safety concern.”
- withdrawn · 2026-03-18 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Vincristine“Replaced with another clinical trial.”
- suspended · 2026-03-16 · National Cancer Institute (NCI) · Vincristine“Pending updated agreements in order to enroll additional participants.”
- terminated · 2026-03-12 · Allarity Therapeutics · Ixabepilone Injection“Company Decision”
- terminated · 2026-03-02 · BeiGene · matched by the registry's drug synonyms“Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern.”
- terminated · 2025-12-16 · Mario Negri Institute for Pharmacological Research · durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)“Low enrolment rate”
- terminated · 2025-12-10 · Spanish Breast Cancer Research Group · Vinorelbine“The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.”
- terminated · 2025-10-23 · European Organisation for Research and Treatment of Cancer - EORTC · Vincristine“Poor accrual”
- withdrawn · 2025-10-03 · Karyopharm Therapeutics Inc · Polatuzumab Vedotin“Sponsor decision”
- terminated · 2025-10-02 · Takeda · matched by the registry's drug synonyms“Phase 1 enrollment was terminated due to dose-limiting toxicities, thus the study was terminated by Sponsor.”
Paediatric incentives and obligations for TUBB1's drugs
For glembatumumab vedotin, vinflunine, polatuzumab vedotin, vinorelbine, vincristine, mirvetuximab soravtansine, vinblastine, paclitaxel poliglumex, ixabepilone, eribulin, brentuximab vedotin, tisotumab vedotin: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · TUBB1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001261-PIP01-11-M07 (Eribulin, Treatment of soft tissue sarcoma): PM: decision on the application for modification of an agreed PIP, 6 Dec 2021; compliance positive 25 Feb 2022; EMEA-000980-PIP01-10-M07 (Brentuximab vedotin, Treatment of anaplastic large cell lymphoma;Treatment of Hodgkin lymphoma): PM: decision on the application for modification of an agreed PIP, 28 Jan 2021; compliance positive 25 Jun 2021; EMEA-002522-PIP01-18 (tisotumab vedotin, Treatment of cervical cancer): W: decision granting a waiver in all age groups for all conditions or indications, 12 Jun 2019; EMEA-000980-PIP04-18 (Brentuximab vedotin, Treatment of Mature T and NK neoplasms (excluding anaplastic large-cell lymphoma and cutaneous Tcell lymphoma)): W: decision granting a waiver in all age groups for all conditions or indications, 8 Oct 2018; +3 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/15/1458 positive 19 Mar 2015: Treatment of ovarian cancer; EU/3/11/939 withdrawn 11 Jan 2012: Treatment of cutaneous T-cell lymphoma; EU/3/08/596 withdrawn 15 Jan 2009: Treatment of Hodgkin's lymphoma; EU/3/18/2013 positive 16 Apr 2018: Treatment of diffuse large B-cell lymphoma; +1 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Polivy: authorised since 16 Jan 2020, orphan medicine; Elahere: authorised since 14 Nov 2024, orphan medicine; Tivdak: authorised since 28 Mar 2025; Adcetris: authorised since 25 Oct 2012; +4 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Vincristine Sulfate, date not given: Acute leukemia; MULTIPLE (in combination); Vinblastine sulfate, 25 Nov 1965: Palliative treatment of malignancies including generalized Hodgkin’s disease, histiocytosis X and testicular germ cell carcinoma; Brentuximab vedotin [Adcetris], 10 Nov 2022: Treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamideRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 766 interventional studies of glembatumumab vedotin, vinflunine, polatuzumab vedotin, vinorelbine, vincristine, mirvetuximab soravtansine, vinblastine, paclitaxel poliglumex, ixabepilone, eribulin, brentuximab vedotin, tisotumab vedotin include patients under 18; 191 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 86 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.